APN 401

Drug Profile

APN 401

Alternative Names: APN401; siRNA-transfected PBMC APN401; siRNA-transfected peripheral blood mononuclear cells - Apeiron

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apeiron Biologics
  • Class Antineoplastics; Cell therapies; Small interfering RNA
  • Mechanism of Action CBLB protein expression inhibitors; RNA interference; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 05 Mar 2018 Phase-II clinical trials in Solid tumours in USA (IV) (Apeiron pipeline, March 2018)
  • 05 Mar 2018 Apeiron Biologics plans a phase II trial for Pancreatic cancer (Apeiron website, March 2018)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top